Vertex gets promising Phase II telaprevir data

Telaprevir combined with older anti-viral treatments peginterferon and ribavirin cured 93 percent to 100 percent of patients with hepatitis C genotype 1 after 48 weeks of treatment, according to Vertex Pharmaceuticals and Johnson & Johnson. The results were unveiled at the European Association for the Study of the Liver in Vienna.

"The majority of genotype 1 patients who undergo their first regimen of pegylated-interferon and ribavirin fail to achieve SVR and are left with few options for subsequent re-treatment of their disease," says Thomas Berg, Medical Development, Hepatology Section, University Clinic, Leipzig, Germany. "Treatment with telaprevir-based regimens in Study 107 resulted in an overall SVR rate of 59 percent across all patients enrolled in the study, with 56 percent of the most difficult-to-treat null responder patients achieving SVR with a 48-week telaprevir-based regimen." Results from a separate Phase III trial of the drug are expected in the third quarter of this year.

- here's Vertex's release
- read this report for more

ALSO: Vertex paid its new CEO Matthew Emmens $19.3 million in his first year on the job. Emmens replaced long-time company CEO and founder Joshua Boger last year. Story

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.